As of February 21, 2025, the FDA updated its drug shortage list, marking the semaglutide injection shortage as resolved.
Semaglutide injections are no longer classified as "currently in shortage," and both 503A and 503B compounders have been assigned deadlines to cease compounding, distributing, or dispensing semaglutide injection products:
503A Pharmacies: Must cease by April 22, 2025 (60 days from the FDA announcement).
503B Outsourcing Facilities: Must cease by May 22, 2025 (90 days from the FDA announcement).
GLP-1 receptor agonists still in shortage include dulaglutide and liraglutide injections.
No significant lawsuits have been filed in response to the FDA’s announcement. However, Novo Nordisk has joined Eli Lilly in the OFA v. FDA lawsuit, submitting an amicus brief supporting opposition to OFA’s motion for a preliminary injunction.